SCHEMBL1266948

SCHEMBL1266948

O=C(c1ccc(NCc2ccc(Cl)cc2)nc1NCc1ccc(Cl)cc1)c1c[nH]c2ncccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 5/20 0.52
▸ DYRK1A Q13627 2/20 0.44
▸ CSF1R P07333 2/20 0.44
▸ PLK4 O00444 1/20 0.44
▸ CHEK1 O14757 1/20 0.44
▸ MAPK13 O15264 1/20 0.44
▸ DAPK3 O43293 1/20 0.44
▸ DYRK3 O43781 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ ROCK2 O75116 1/20 0.44
▸ RPS6KA5 O75582 1/20 0.44
▸ PRKD3 O94806 1/20 0.44
▸ PAK4 O96013 1/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ NTRK1 P04629 1/20 0.44
▸ PRKCG P05129 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ FYN P06241 1/20 0.44
▸ CDK1 P06493 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267869 0.91 KDR (0.52) KDRDYRK1ACSF1RPLK4CHEK1
SCHEMBL12303976 0.89 KDR (0.51) KDRDYRK1ACSF1RPLK4CHEK1
SCHEMBL2181491 0.87 KDR (0.49) KDRDYRK1ACSF1RPLK4CHEK1
SCHEMBL18400497 0.77 KDR (0.48) KDRDYRK1ACSF1RPLK4CHEK1
SCHEMBL411608 0.77 KDM4E (0.50) KDRDYRK1ACSF1RPLK4CHEK1
SCHEMBL1268227 0.76 KDR (0.49) KDRMAPK13MAPK12ADORA2AMAP2K1
SCHEMBL15530165 0.76 KDR (0.55) KDRMEN1GABRPGABRDPOLB
SCHEMBL2180397 0.73 CSF1R (0.53) KDRDYRK1ACSF1RPLK4CHEK1
SCHEMBL27708260 0.73 MAP2K1 (0.71) KDRDYRK1ACDK2CLK2CDK5
SCHEMBL1266664 0.73 CSF1R (0.55) KDRDYRK1ACSF1RPLK4CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 — — US disclosed
US-9550768-B2 Kinase modulation and indications therefor PLEXXIKON INC. (US) 2017-01-24 — — US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 — — US disclosed
US-9169250-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2015-10-27 — — US disclosed
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2015-09-24 — — US disclosed
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2014-08-28 — — US disclosed
US-8722702-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2014-05-13 — — US disclosed
US-20130274259-A1 KINASE MODULATION AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2013-10-17 — — US disclosed
US-20130178473-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. (US) 2013-07-11 — — US disclosed
US-8461169-B2 Compounds modulating c-fms and/or c-kit activity PLEXXIKON INC. (US) 2013-06-11 — — US disclosed
US-8404700-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2013-03-26 — — US disclosed
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC 2012-12-06 — — US disclosed
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY PLEXXIKON INC. 2011-09-22 — — US disclosed
US-20110166174-A1 COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR PLEXXIKON, INC. 2011-07-07 — — US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 — — US disclosed
US-7846941-B2 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. (US) 2010-12-07 — — US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US disclosed
EP-1885723-A2 PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2008-02-13 — — EP disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 — — US disclosed
WO-2007013896-A2 PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274259-A1 KINASE MODULATION AND INDICATIONS THEREFOR FLT3, MET, BTK KDR 43/4885DYRK1A 2190/4885CSF1R 33/4885
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 KDR 21/4885DYRK1A 3201/4885CSF1R 4/4885
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 KDR 21/4885DYRK1A 3201/4885CSF1R 4/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 KDR 21/4885DYRK1A 3201/4885CSF1R 4/4885
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 KDR 21/4885DYRK1A 3201/4885CSF1R 4/4885
US-20110166174-A1 COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 KDR 18/4885DYRK1A 2997/4885CSF1R 7/4885
US-20130178473-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 KDR 21/4885DYRK1A 3201/4885CSF1R 4/4885
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY KIT, FLT3, FER KDR 31/4885DYRK1A 2631/4885CSF1R 10/4885
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 KDR 21/4885DYRK1A 3201/4885CSF1R 4/4885
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor KIT, FLT3, FLT1 KDR 18/4885DYRK1A 2997/4885CSF1R 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback